

# 1 **Circulatory Cytokines and Chemokines Profile in Human Coronaviruses:**

## 2 **A systematic review and meta-analysis**

3 Ayat Zawawi<sup>1</sup>, Abdallah Y Naser<sup>2</sup>, Hassan Alwafi<sup>3</sup>, \*Faisal Minsahwi<sup>4</sup>

### 4 **Author affiliations:**

5 <sup>1</sup>Faculty of Applied Medical Sciences, King Abdul Aziz University, Jeddah, Saudi Arabia,

6 <sup>2</sup>Department of Applied Pharmaceutical Sciences and Clinical Pharmacy, Faculty of Pharmacy, Isra

7 University, Amman, Jordan, <sup>3</sup>Faculty of Medicine, Umm Al-Qura University, Makkah, Saudi

8 Arabia, <sup>4</sup>Department of Laboratory Medicine, Faculty of Applied Medical Sciences, Umm

9 Al-Qura University, Makkah, Saudi Arabia

10

### 11 **\* Correspondence author**

12 Dr. Faisal Minshawi

13 Assistant Professor of Immunology

14 Laboratory Medicine, Faculty of Applied Medical Science

15 Umm Al-Qura University, Abidiyyah, Makkah, KSA

16 [fominshawi@uqu.edu.sa](mailto:fominshawi@uqu.edu.sa)

17 +966 5555 328 75

18

### 19 **Keywords**

20 Cytokine storm; Inflammatory cytokines; COVID-19; MERS; SARS; SARS-CoV-2

21

### 22 **Abstract**

23 **Background:** SARS, MERS, and COVID-19 share similar characteristics as the genetic  
24 homology of SARS-CoV-2 compared to SARS-CoV and MERS-CoV is 80% and 50%  
25 respectively and cause similar clinical features. Uncontrolled release of proinflammatory  
26 mediators (cytokine storm) by activated immune cells in SARS, MERS, and COVID-19 leads  
27 to severe phenotype development.

28 **Aim:** This systematic review and meta-analysis aimed to evaluate the inflammatory  
29 cytokines profile associated with severe human coronavirus diseases, including three strains:  
30 MERS-CoV, SARS-CoV SARS-CoV-2, in severe patients.

31 **Method:** PubMed, Embase, and Cochrane Library databases were searched up to July 2020.  
32 Randomized and Observational studies reporting the inflammatory cytokines associated with  
33 severe and non-severe human coronavirus diseases, including MERS-CoV, SARS-CoV  
34 SARS-CoV-2 were included. Two reviewers independently screened articles, extracted data,  
35 and assessed the quality of included studies. Meta-analysis was performed using a random-  
36 effects model with a 95% confidence interval (CI) to estimate the pooled mean of  
37 inflammatory biomarkers.

38 **Results:** A high level of circulating IL-6 could be associated with the severity of the three  
39 strains of coronaviruses infection. TNF, IL-10, and IL-8 is associated with the severity of  
40 COVID-19. Increased circulating levels of CXCL10/IP10 and CCL2/MCP-1 might also be  
41 related to the severity of MERS.

42 **Conclusion:** This study suggests that the immune response and immunopathology in the  
43 three severe human coronavirus strains are similar to some extent. These findings highlight  
44 that nearly all studies reporting severe cases of SARS, MERS, and COVID-19 have been  
45 associated with elevated levels of IL-6, which could be used as a potential therapeutic target  
46 to improve patients' outcomes in severe cases.

47

## 48 **Introduction**

49 Coronavirus disease 2019 (COVID-19), has been characterised as the third human  
50 coronavirus (hCoV) outbreak in only two decades (1). Coronaviruses are enveloped, single-  
51 stranded RNA viruses that infect the lower respiratory tract (2). Severe Acute Respiratory  
52 Syndrome (SARS) was the first global epidemic of the twenty-first century caused by SARS-  
53 CoV (3, 4). For the first time in Hong Kong, in March 2003, the disease broke out and has  
54 spread through the world, including Asia, Europe, and the United States (5). Nearly a decade  
55 following the SARS epidemic, the Middle East Respiratory Syndrome (MERS) caused by  
56 MERS-CoV emerged in June 2012, in Saudi Arabia. The MERS outbreak also rapidly spread  
57 to more than 20 countries (6). Bats have been known to be the natural reservoir of SARS and  
58 MERS. Dromedary camels have also been found to be the zoonotic reservoir to transmit  
59 MERS to humans (7). COVID-19 is the newest emerging infectious disease (8). The infection  
60 began in Wuhan, China, in December 2019, (9). The novel coronavirus has infected over 100  
61 million people with around 2 million death around the world (10), causing a more serious  
62 global threat than either of its two predecessors.

63 These three human coronaviruses share similar characteristics as the genetic homology of  
64 SARS-CoV-2 compared to SARS-CoV and MERS-CoV is 80% and 50%, respectively (11).  
65 These three respiratory infectious diseases are also associated with significant morbidity and  
66 mortality as they are highly transmissible, primary through respiratory droplets and close  
67 contact (12). However, MERS is relatively inefficiently transmitted to humans compared to  
68 SARS and COVID-19 (13, 14). Conversely, SARS and COVID-19 were characterised by a  
69 relatively low mortality rate than MERS (15). This is likely related to the viral kinetic; older  
70 people are more common to get MERS infection and comorbid illness (15).

71 The three respiratory infectious diseases SARS, MERS, and COVID-19 cause similar clinical  
72 features ranged from asymptomatic to severe illness that requires intubation and intensive  
73 care management (16, 17). The severity of these diseases is linked to age and chronic illness,  
74 including diabetes, hypertension, cardiovascular disease, chronic respiratory disease, and  
75 cancer (18). Whereas viral pneumonia, acute respiratory distress syndrome, and multiple  
76 organ failure are common in these diseases' later stages (19-21). Other non-specific  
77 laboratory tests including leukopenia, lymphopenia, thrombocytopenia, and elevated serum  
78 amino transaminases, are also common in SARS, MERS, and COVID-19 infections (22).

79 It has also been reported that uncontrolled release of proinflammatory mediators (cytokine  
80 storm) by activated immune cells in SARS (23), MERS (24) and COVID-19 (25) leads to the  
81 development of severe phenotype. Given the potential overlap in presentation and

82 manifestation among severe hCoVs infection, as such absence of effective treatment, it is  
83 essential to understand the immunopathological aspect such as cytokine storm syndrome  
84 (CSS). Therefore, this systematic review and meta-analysis aimed to compare the  
85 inflammatory biomarkers associated with severe human coronavirus diseases, including three  
86 significant stains: MERS-CoV, SARS-CoV, SARS-CoV-2, which may indicate a distinct  
87 inflammatory profile and, accordingly, identifying potential treatment options in severe  
88 patients.

89

## 90 **Methods**

91 The systematic review and meta-analysis were carried out following the Meta-analysis of  
92 Observational Studies in Epidemiology (MOOSE) guidelines (26) and reported following the  
93 Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA) statement  
94 (27). The protocol of the study was registered with PROSPERO (Provisional registration  
95 number CRD42020209931).

## 96 **Databases and search strategy**

97 An extensive search strategy summarised in Figure 1 was developed to identify relevant  
98 studies. A detailed electronic search on bibliographic databases including Medline, Embase,  
99 and Cochrane Library databases was performed from inception to July 2020. Keywords,  
100 Emtree and MeSH terms were used with both English and American spellings. The search  
101 strategy covered the following keywords: cytokines, inflammatory biomarkers, SARS-CoV,  
102 SARS-CoV-2, Severe Acute Respiratory Syndrome, Middle East Respiratory Syndrome  
103 Coronavirus, and COVID-19.

## 104 **Eligibility criteria**

105 The selection of included studies was based on an inclusion/exclusion criteria. Inclusion  
106 criteria includes any randomised or observational studies that assessed the concentration level  
107 of cytokines and chemokines in peripheral blood of patients with severe SARS, MERS and  
108 COVID-19. Severe patients or critical were defined as patients who had a respiratory failure,  
109 required mechanical ventilation, shock, combining other organ failures, and intensive care  
110 unit (ICU) were needed. Conference proceedings, reviews, studies not published in English,  
111 animal studies and *in vitro* cytokine production in stimulated cells were excluded. Studies  
112 that did not clearly differentiate between severity or did not report the mean and standard  
113 deviation or median of cytokine parameter levels were also excluded.

## 114 **Data extraction**

115 Initially, all the researchers (A.Z, A.N, H.A and F.M.) screened the title and abstract of each

116 study independently to assess if it is eligible based on the inclusion/exclusion criteria.  
117 Subsequently, all the researchers (A.Z, A.N, H.A and F.M.) conducted a two-step full-text  
118 literature search independently to assess eligibility further. Data extraction from the relevant  
119 studies was performed independently by all researchers using a form created for this study.  
120 The following demographic details were extracted from each study; study details, data  
121 source, year of publication, sample size, age and sex. The mean, median, standard error, IQR,  
122 and range of the following cytokines and chemokines were also extracted; IL-1, IL-2, IL-4,  
123 IL-6, IL-8, IL-10, IL-17, TNF, INFg, RANTS, CCL2/MCP-1, CXCL10/IP10, and TGFβ.

#### 124 **Quality assessment:**

125 Methodological quality and risk of bias were assessed using the Newcastle Ottawa Scale for  
126 Observational Studies (28), which was modified to meet the requirement of this study (29). A  
127 total of six criteria were evaluated: representativeness of the population, sample size,  
128 statistical analysis, missing data, methodology to report the outcome of interest and methods  
129 to detect or report the outcome of interest. Each criterion was rated using a scale ranging  
130 from 0 to 3, where 3 represented the highest quality. The highest possible overall score is 18.  
131 In addition, we categorised the quality assessment score into three categories: good quality  
132 (>12), moderate quality (>6) and low quality (≤6) points.

#### 133 **Data Synthesis and Analysis**

134 Descriptive statistics were used to describe the demographic characteristics and the  
135 quantitative mean concentration of the inflammatory biomarkers reported in each study. To  
136 standardise the data for meta-analysis, we estimated the mean cytokine concentrations from  
137 the studies that reported the median using the following formula: calculating the mean: if the  
138 sample size  $\leq 25$  ( $X = \frac{a + 2m + b}{4}$ ), if the sample size  $> 25$  ( $X = m$ ), and calculating the  
139 variance: if the sample size  $\leq 15$  ( $S^2 = \frac{1}{12} \left[ \frac{(a - 2m + b)^2}{4} + (b - a)^2 \right]$ ), if the sample size 15-70  
140 ( $S = \frac{R}{4}$ ) and if the sample size  $\geq 70$  ( $S = \frac{R}{6}$ ) (30). A random-effect model was used to estimate  
141 the mean concentration of biomarkers (31). Heterogeneity among included studies in the  
142 meta-analysis was assessed using the standard  $\chi^2$  tests and the  $I^2$  statistic. If high  
143 heterogeneity was indicated ( $I^2 \geq 75\%$ ), a systematic narrative synthesis was provided. All  
144 analysis was performed using STATA 15.0.

145 \*m = median, a = minimum, b = maximum, X = mean, S = variance, R = range (b-a)

#### 146 **Results**

##### 147 **Studies selection, characteristics and quality assessment**

148 A total of 4282 studies were identified through the initial online search in databases (Fig 1).  
149 Of these, 666 studies were duplicates. Title and abstract screening identified 34 studies for  
150 final full-text review using inclusion/exclusion criteria. Finally, the search yielded 18 studies  
151 that met the inclusion criteria. Of these, fifteen studies were conducted on COVID-19, two  
152 studies on MERS, and one study on SARS. The fifteen COVID-19 studies included 538  
153 severe patients with around (67%) male and (33%) females included in the final analysis.  
154 One SARS (47) and two MERS studies (48, 49) had smaller number of patients. The SARS  
155 study included 30 severe patients, 70% of them were male and 30 % were females.  
156 Moreover, the two MERS studies (48, 49) had 15 severe patients, with round 80% male and  
157 20% females. The final 18 studies also included 1922 non-severe individuals as controls. 13  
158 out of the 18 studies were conducted in China, 3 studies in South Korea, 1 study in Germany,  
159 and 1 study in Ireland. Most of the laboratory tests were conducted after admission. The  
160 characteristics of the included studies are summarised in Table 1. Overall, the quality of the  
161 included studies was good. The quality assessment score for the included studies ranged from  
162 12 as the lowest score to 18 as the highest score recorded. Most of the studies (94.4%)  
163 included in this review were of good quality and scored >12 (n = 17), while one study was of  
164 moderate quality. The details of the quality assessments are presented in Table 1 and  
165 Supplementary table 1

## 166 **The level of circulating cytokines in COVID-19, MERS and SARS patients**

### 167 **COVID-19**

168 The dynamic changes of circulating cytokines (IL-1, IL-2, IL-6, TNF and IFN- $\gamma$ , IL-4, IL-10,  
169 and IL-17) were analysed in the 18 included studies. IL-6 concentrations were reported in  
170 fifteen COVID-19 studies, one SARS study, and two MERS studies. Remarkably, all but one  
171 study showed a significant elevation on the level of IL-6 in severe COVID-19 patients  
172 compared to non-severe groups. The level of circulating IL-6 was also significantly high in  
173 severe SARS patients ( $517\pm 769$  pg/ml) compared to non-severe groups ( $163\pm 796$  pg/ml)  
174 (47). Furthermore, the two studies (48, 49) that measured the level of circulating cytokines in  
175 severe MERS patients showed an elevation on the level of IL-6 in severe MERS patients  
176 compared to non-severe groups.

177 Other cytokines were substantially elevated in patients with severe COVID-19 patients but  
178 not in patients with severe SARS and MERS. For example, three studies (32, 34, 38) out of  
179 eight showed a significant elevation on TNF level in severe COVID-19 patients compared to  
180 non-severe groups. The concentrations level of IL-10 was also measured in seven studies (33-

181 35, 38, 41, 43, 46), of which ten studies reported a significant difference between severe  
182 COVID-19 patients compared to non-severe groups. In contrast, (47) and (48, 49) showed  
183 that the level of TNF and IL-10 cytokines were not significantly elevated in patients with  
184 severe SARS and MERS compared to a non-severe group, respectively.

185 Most of the other cytokines were not comparatively high in severe patients with COVID-19,  
186 SARS, and MERS. For example, one study (46) out of six showed that the level of IFN- $\gamma$  was  
187 significantly high in patients with severe COVID-19 ( $1.9\pm 0.3$  pg/ml) compared to non-severe  
188 groups ( $1.2\pm 0.1$  pg/ml). IFN- $\gamma$  concentrations were also not elevated in patients with severe  
189 SARS than the non-severe group (47). Similar results were seen on IL-4. One study (34) out  
190 of six showed that the level of IL-4 in severe COVID-19 patients was significantly higher  
191 ( $3.3\pm 0.2$  pg/ml) than non-severe groups ( $3.4\pm 0.2$  pg/ml). However, (47) reported that IL-4  
192 concentration in patients with severe SARS was ( $110\pm 12$  pg/ml), similar to that for a non-  
193 severe group ( $109\pm 13$  pg/ml). The level of IFN- $\gamma$  and IL-4 were not available in any MERS  
194 studies.

195 The concentrations of IL-1, IL-2, and IL-17 were only reported in four (32, 37, 39, 43)  
196 COVID-19 studies. Of these, one study (39) showed a significant difference between patients  
197 with severe COVID-19 ( $40.8\pm 10.4$  pg/ml) and non-severe groups ( $13.7\pm 5.8$  pg/ml). Similar  
198 results were seen in IL-2. One study (43) out of five reported a significant difference between  
199 severe COVID-19 patients with an average of  $8.1\pm 6.03$  pg/ml, and non-severe groups,  
200 averaging  $2.25\pm 1.01$  pg/ml. The only two studies (41, 43) that measured the level of IL-17 in  
201 severe COVID-19 patients also showed no significant difference between severe COVID-19  
202 patients and non-severe groups. Altogether, our data suggest that a high level of circulating  
203 IL-6, TNF, and IL-10 might be associated with the severity of COVID-19. While increased  
204 IL-6 only might be related to the severity of SARS and MERS.

#### 205 **The level of circulating chemokines in COVID-19, MERS, and SARS patients**

206 The concentrations of circulating inflammatory chemokine IL-8 were reported in five (32,  
207 37-39, 43, 47) COVID-19 studies and one (47) SARS study. Remarkably, four (32, 37-39,  
208 43) out of the five COVID-19 studies reported a significant elevation in the level of IL-8 in  
209 severe COVID-19 patients compared to non-severe groups. In contrast, the one study (47)  
210 conducted in SARS patients reported a significant reduction in the level of IL-8 in severe  
211 SARS patients with an average of  $143\pm 41$  pg/ml compared to the non-severe group averaging  
212  $165\pm 51$  pg/ml.

213 The concentration level of C-X-C motif chemokine 10/interferon-gamma-induced protein 10  
214 (CXCL10/IP10) and chemokine ligand 2/monocyte chemoattractant protein-1 (CCL2/MCP-  
215 1) chemokines were only reported in two MERS studies (48, 49). The concentrations level of  
216 CXCL10/IP10 and CCL2/MCP-1 were significantly high in patients with severe MERS than  
217 in non-severe groups. Although the number of studies measuring the level of chemokines in  
218 patients with severe COVID-19, SARS and/or MERS is limited, the data suggest that  
219 circulating IL-8 chemokine might be associated with the severity of COVID-19. Moreover,  
220 the level of circulating CXCL10/IP10 and CCL2/MCP-1 chemokines might also be related to  
221 the severity of MERS.

222 The 18 studies included in the meta-analysis had a high-level of heterogeneity (I-squared =  
223 99.9 %). There was considerable variation between studies in terms of geographical  
224 locations, study designs, time of blood collection, variable assays used to measure the level of  
225 cytokines and data source in both severe and non-severe cases (Supplementary figures 1)

226

## 227 **Discussion**

228 Emerging studies focused on selectively targeting elevating inflammatory cytokines for  
229 treating cytokine release syndrome in hCoVs (50). However, the mutual cytokine profile  
230 among hCoV stains, which could improve the hyperinflammatory state in critically ill hCoV  
231 patients is undetermined. In addition to unanswered questions about the mechanistic role of  
232 the cytokine storm shared between the three hCoVs. Therefore, this systemic review and  
233 meta-analysis were performed to analyse circulatory cytokines and chemokine profiles in  
234 patients with severe hCoVs.

235 Among the inflammatory parameters, our systematic review analysis demonstrated a marked  
236 elevation in the level of circulating IL-6 and TNF in severe COVID-19 and MERS patients in  
237 comparison to non-severe groups. Most of the included studies also showed a significant  
238 elevation of circulating IL-10 in severe COVID-19 patients compared to non-severe groups.  
239 However, due to the limited number of studies conducted on SARS, we could not find a  
240 strong association of high levels of circulatory IL-6 and TNF and IL-10 with the severity of  
241 the disease, which could be an essential factor for further investigation. A previous study on  
242 mice showed that SARS spike protein induced the secretion of high levels of IL-6 and TNF  
243 through the NF- $\kappa$ B pathway (51). Others indicated that MERS infected human monocyte  
244 derived-macrophages induced the secretion of high levels of TNF and IL-6 (52).

245 IL-6 and TNF are pleiotropic cytokines produced by different cell types during the acute  
246 phase of the infection (53, 54). Apart from its pleiotropic property, IL-6 deteriorates

247 inflammation reaction and activates the coagulation pathway by inducing complement  
248 components and several acute-phase proteins including, C-reactive protein (CRP),  
249 antitrypsin, and fibrinogen (55). Previous studies have also indicated that the high level of  
250 circulatory IL-6 is considered an early marker of morbidity and mortality in lung diseases  
251 (56). A recent study by Zhua et al. reported the significant role of IL-6 as an independent  
252 COVID-19 risk factor using multivariate logistic regression analyses (46). Other studies  
253 suggested that the considerable elevation of IL-6 cytokine in severe COVID-19 patients is  
254 linked to the massive mucus production by stimulating the expression of the two predominant  
255 mucin genes (MUC5AC and MUC5B) in tracheobronchial epithelial cells (57, 58). IL-6  
256 elevation might also be related to endothelial activation and precipitation of a pulmonary  
257 immune-mediated thrombosis (59). Moreover, IL-6 has been found to be significantly  
258 correlated with the anti-inflammatory cytokine, IL-10, which may reflect self-protection  
259 during cytokine release syndrome (46). It has also been reported that the level of anti-  
260 inflammatory cytokine could directly contribute to elaborate sepsis-induced  
261 immunosuppression, which amplifies the susceptibility to secondary infections (60).  
262 Consequently, the intense focus on treating severe COVID-19 cases with an anti-IL-6  
263 receptor (IL-6R) is emerging and showed beneficial results in clinical trials (61).  
264 Less is known about chemokines spectrum in human coronavirus compared to cytokine  
265 production. Thus, it is hard to determine the importance of chemokines in hCoVs disease  
266 progression. However, our systematic review showed similar or higher levels of chemokines  
267 detected in hCoVs infected patients. A marked overproduction of plasma IL-8 was  
268 demonstrated in patients infected with severe COVID-19. Whereas CXCL10/IP10 and  
269 CCL2/MCP-1 were detected in the blood of patients infected with severe MERS. However,  
270 other studies that were not included in our systematic review reported elevated levels of IL-8  
271 in the blood of patients infected with MERS and SARS (52, 62, 63) and CXCL10/IP10 and  
272 CCL2/MCP-1 in SARS (64) and COVID-19 (65, 66) infected patients.  
273 IL-8 and CCL2/MCP-1 are secreted by many cells in response to IL-6 and TNF mediated  
274 cytokines (67, 68). Whereas CXCL10/IP10 is secreted by many cells, including monocytes,  
275 endothelial cells and fibroblast in response to IFN- $\gamma$  (69). These chemokines and others play  
276 essential roles in the pathogenesis of diseases characterized by thrombosis in addition to  
277 monocytes, macrophages, neutrophils and lymphocytes infiltration (70). Moreover, anti-  
278 CXCL10/IP10 is in a clinical trial as a promising approach to treat cardiovascular event (71).  
279 Thus, the findings of high levels of chemokines in the serum of critically ill hCoVs patients

280 provide some hints that chemokines could be used as biomarkers of the severity of hCoV  
281 diseases and can serve as targets for the development of hCoVs chemotherapeutics,  
282 especially in patients with thrombotic events.

283 Our demographic data also demonstrated that most of the hCoVs severe cases are among old  
284 male people, which is also in line with previous studies. It has been previously known that  
285 older people with comorbidity are more vulnerable than young people to develop a more  
286 advance and severe human coronavirus related disease (72). It is believed that dysregulated  
287 innate immunity and deficiency in adaptive immune response in older people, mostly males,  
288 could play an essential role in this observation (72). For instance, Torcia et al. demonstrated  
289 that peripheral blood mononuclear cells (PBMCs) from males stimulated with influenza and  
290 Herpes-simplex-1 viruses induced the production of high levels of IL-10 compared to  
291 females (73). Other studies showed that males had higher levels of proinflammatory  
292 cytokines (e.g., TNF) and chemokines (e.g., CXCL10) following lipopolysaccharide  
293 stimulation (74). In contrast, females had a higher number of proliferating T-cells and B-cells  
294 *in vitro* and antibody response to influenza vaccination than males (75). Previous studies also  
295 demonstrated that patients with comorbidities such as diabetes, asthma, and hypertension are  
296 at higher risk of mortality because of the excessive production of inflammatory cytokines,  
297 including IL-2R, IL-10, and TNF (76-78). These studies and others highlighted that gender,  
298 and age-specific innate and adaptive immunity and comorbidity might affect inflammation  
299 reaction of hCoVs patients, immunotherapy, and immune response to hCoVs vaccination.

300

### 301 **Limitation of the study**

302 Several limitations exist within our study; the most important is the observational nature of  
303 studies and significant heterogeneity in study results. However, high statistical heterogeneity  
304 is more frequent in meta-analyses of prevalence and descriptive studies (79). This can be  
305 explained because of the different patient populations, underlying comorbidities and  
306 coinfections, variant treatments and follow-up. The different time of blood collections,  
307 control donors, and cytokine detection assays can also explain the heterogeneity. Another  
308 significant limitation is the variability in laboratory assays used to measure the level of serum  
309 cytokines, as local laboratories have different normal ranges based on local data. This  
310 confounding variable can somewhat undermine our results and thus, our data should be  
311 interpreted as such, keeping in mind this important limitation.

312 The number of studies included on SARS and MERS compared to COVID-19 were low.  
313 However, this can be explained as the COVID-19 infection caused a major threat to the  
314 whole population compared to SARS and MERS.

315

### 316 **Conclusions and future directions**

317 Despite these limitations, our study in meta-analysis remained consistent with observational  
318 data analysis, demonstrating the importance of cytokine release syndrome and worsen the  
319 disease outcome in the three hCoV infectious diseases. Although not all the included studies  
320 demonstrated a significant elevation in the level of pro-inflammatory and anti-inflammatory  
321 cytokines such as IL-6, IL-10 and TNF, in severe compared to non-severe groups. It is also  
322 worth considering that the less noticeable cytokine elevations in the three hCoV infections  
323 might suggest a regulated or insufficient inflammatory response to overwhelming viral  
324 infection such as IFN- $\gamma$ .

325 Although the degree of cytokinaemia in patients with severe SARS, MERS, and COVID-19  
326 is markedly higher than that seen in non-severe groups, there are still unanswered questions  
327 regarding the mechanistic role of cytokine storm shared in the three hCoVs. We believe that  
328 the immune response and immunopathology in COVID-19 are similar to some extent to  
329 SARS and MERS. These findings could shed light on the cytokine release syndrome in the  
330 progression of hCoVs and may indicate the type of immune response or pathophysiological  
331 events involved in these diseases with a potential therapeutic strategy to improve patients'  
332 outcomes. We recommend using a combination of existing, approved therapies with proven  
333 safety profiles such as IL-6 blockade signaling (tocilizumab) for the treatment of  
334 hyperinflammation during the severe SARS, MERS, and COVID-19 infections

335

### 336 **Data Availability**

337 All data sets generated for this study are included in the manuscript/supplementary files.

338

### 339 **Author Contribution**

340 Conception and design FM; Acquisition of the data: AZ, AYN, HA, and FM; Analysis and  
341 interpretation of the data: AZ, AYN, HA, and FM. Drafting and revising the article: AZ,  
342 AYN, HA, and FM. All authors contributed to the article and approved the submitted version.

343

### 344 **Funding**

345 This research received no specific grant from any funding agency in the public, commercial,  
346 or not-for-profit sectors

347

348

### 349 **Supplementary materials**

350 The Supplementary Material for this article can be found online at:

351

### 352 **Conflict of interest**

353 The authors declare no competing interest.

354

### 355 **Reference**

- 356 1. Guarner J. Three emerging coronaviruses in two decades: the story of SARS, MERS,  
357 and now COVID-19: Oxford University Press US; 2020 [
- 358 2. Egloff M-P, Ferron F, Campanacci V, Longhi S, Rancurel C, Dutartre H, et al. The  
359 severe acute respiratory syndrome-coronavirus replicative protein nsp9 is a single-stranded  
360 RNA-binding subunit unique in the RNA virus world. *Proceedings of the National Academy  
361 of Sciences*. 2004;101(11):3792-6.
- 362 3. Cherry JD, Krogstad P. SARS: the first pandemic of the 21st century. *Pediatr Res*.  
363 2004;56(1):1-5.
- 364 4. Ksiazek TG, Erdman D, Goldsmith CS, Zaki SR, Peret T, Emery S, et al. A novel  
365 coronavirus associated with severe acute respiratory syndrome. *N Engl J Med*.  
366 2003;348(20):1953-66.
- 367 5. Skowronski DM, Astell C, Brunham RC, Low DE, Petric M, Roper RL, et al. Severe  
368 acute respiratory syndrome (SARS): a year in review. *Annu Rev Med*. 2005;56:357-81.
- 369 6. Raj VS, Osterhaus AD, Fouchier RA, Haagmans BL. MERS: emergence of a novel  
370 human coronavirus. *Curr Opin Virol*. 2014;5:58-62.
- 371 7. Nowotny N, Kolodziejek J. Middle East respiratory syndrome coronavirus (MERS-  
372 CoV) in dromedary camels, Oman, 2013. *Euro Surveill*. 2014;19(16):20781.
- 373 8. Spinelli A, Pellino G. COVID-19 pandemic: perspectives on an unfolding crisis. *Br J  
374 Surg*. 2020;107(7):785-7.
- 375 9. Cucinotta D, Vanelli M. WHO Declares COVID-19 a Pandemic. *Acta Biomed*.  
376 2020;91(1):157-60.
- 377 10. Organization WH. Coronavirus disease (COVID-19) Weekly Epidemiological Update  
378 and Weekly Operational Update 2020 [
- 379 11. Lu R, Zhao X, Li J, Niu P, Yang B, Wu H, et al. Genomic characterisation and  
380 epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding.  
381 *The Lancet*. 2020;395(10224):565-74.
- 382 12. Cunha CB, Opal SM. Middle East respiratory syndrome (MERS): a new zoonotic  
383 viral pneumonia. *Virulence*. 2014;5(6):650-4.
- 384 13. Zumla AI, Memish ZA. Middle East respiratory syndrome coronavirus: epidemic  
385 potential or a storm in a teacup? *Eur Respir J*. 2014;43(5):1243-8.
- 386 14. Chen J. Pathogenicity and transmissibility of 2019-nCoV-A quick overview and  
387 comparison with other emerging viruses. *Microbes Infect*. 2020;22(2):69-71.
- 388 15. Hui DS, Memish ZA, Zumla A. Severe acute respiratory syndrome vs. the Middle  
389 East respiratory syndrome. *Curr Opin Pulm Med*. 2014;20(3):233-41.

- 390 16. Zhu Z, Lian X, Su X, Wu W, Marraro GA, Zeng Y. From SARS and MERS to  
391 COVID-19: a brief summary and comparison of severe acute respiratory infections caused by  
392 three highly pathogenic human coronaviruses. *Respiratory research*. 2020;21(1):1-14.
- 393 17. Channappanavar R, Perlman S. Pathogenic human coronavirus infections: causes and  
394 consequences of cytokine storm and immunopathology. *Seminars In Immunopathology*.  
395 2017;39(5):529-39.
- 396 18. Lei S, Jiang F, Su W, Chen C, Chen J, Mei W, et al. Clinical characteristics and  
397 outcomes of patients undergoing surgeries during the incubation period of COVID-19  
398 infection. *EClinicalMedicine*. 2020;21:100331.
- 399 19. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients  
400 infected with 2019 novel coronavirus in Wuhan, China. *Lancet*. 2020;395(10223):497-506.
- 401 20. Guery B, Poissy J, el Mansouf L, Sejourne C, Ettahar N, Lemaire X, et al. Clinical  
402 features and viral diagnosis of two cases of infection with Middle East Respiratory Syndrome  
403 coronavirus: a report of nosocomial transmission. *Lancet*. 2013;381(9885):2265-72.
- 404 21. Booth CM, Matukas LM, Tomlinson GA, Rachlis AR, Rose DB, Dwosh HA, et al.  
405 Clinical features and short-term outcomes of 144 patients with SARS in the greater Toronto  
406 area. *JAMA*. 2003;289(21):2801-9.
- 407 22. Petrosillo N, Viceconte G, Ergonul O, Ippolito G, Petersen E. COVID-19, SARS and  
408 MERS: are they closely related? *Clinical Microbiology and Infection*. 2020.
- 409 23. Cameron MJ, Bermejo-Martin JF, Danesh A, Muller MP, Kelvin DJ. Human  
410 immunopathogenesis of severe acute respiratory syndrome (SARS). *Virus Res*.  
411 2008;133(1):13-9.
- 412 24. Lau SKP, Lau CCY, Chan KH, Li CPY, Chen H, Jin DY, et al. Delayed induction of  
413 proinflammatory cytokines and suppression of innate antiviral response by the novel Middle  
414 East respiratory syndrome coronavirus: implications for pathogenesis and treatment. *J Gen  
415 Virol*. 2013;94(Pt 12):2679-90.
- 416 25. Mangalmurti N, Hunter CA. Cytokine Storms: Understanding COVID-19. *Immunity*.  
417 2020;53(1):19-25.
- 418 26. Stroup DF, Berlin JA, Morton SC, Olkin I, Williamson GD, Rennie D, et al. Meta-  
419 analysis of observational studies in epidemiology: a proposal for reporting. *Jama*.  
420 2000;283(15):2008-12.
- 421 27. Picot J, Hartwell D, Harris P, Mendes D, Clegg A, Takeda A. The preferred reporting  
422 items for systematic reviews and meta-analyses checklist. *The Effectiveness of Interventions  
423 to Treat Severe Acute Malnutrition in Young Children: A Systematic Review: NIHR Journals  
424 Library*; 2012.
- 425 28. Wells GA, Shea B, O'Connell Da, Peterson J, Welch V, Losos M, et al. The  
426 Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-  
427 analyses. Oxford; 2000.
- 428 29. Park JY, Howren AM, Zusman EZ, Esdaile JM, De Vera MA. The incidence of  
429 depression and anxiety in patients with ankylosing spondylitis: a systematic review and meta-  
430 analysis. *BMC rheumatology*. 2020;4(1):1-8.
- 431 30. Hozo SP, Djulbegovic B, Hozo I. Estimating the mean and variance from the median,  
432 range, and the size of a sample. *BMC medical research methodology*. 2005;5(1):13.
- 433 31. Deeks JJ, Higgins JP, Altman DG, Group CSM. Analysing data and undertaking  
434 meta-analyses. *Cochrane handbook for systematic reviews of interventions*. 2019:241-84.
- 435 32. Chen G, Wu D, Guo W, Cao Y, Huang D, Wang H, et al. Clinical and immunological  
436 features of severe and moderate coronavirus disease 2019. *Journal of Clinical Investigation*.  
437 2020;130(5):2620-9.

- 438 33. Gao Y, Li T, Han M, Li X, Wu D, Xu Y, et al. Diagnostic utility of clinical laboratory  
439 data determinations for patients with the severe COVID-19. *Journal of Medical Virology*.  
440 2020;92(7):791-6.
- 441 34. Han H, Ma Q, Li C, Liu R, Zhao L, Wang W, et al. Profiling serum cytokines in  
442 COVID-19 patients reveals IL-6 and IL-10 are disease severity predictors. *Emerging*  
443 *Microbes & Infections*. 2020;9(1):1123-30.
- 444 35. He S, Zhou C, Lu D, Yang H, Xu H, Wu G, et al. Relationship between Chest CT  
445 manifestations and immune response in COVID-19 patients. *International Journal of*  
446 *Infectious Diseases*. 2020;20:20.
- 447 36. Herold T, Jurinovic V, Arnreich C, Lipworth BJ, Hellmuth JC, Bergwelt-Baildon  
448 MV, et al. Elevated levels of IL-6 and CRP predict the need for mechanical ventilation in  
449 COVID-19. *Journal of Allergy and Clinical Immunology*. 2020.
- 450 37. Liu Y, Liao W, Wan L, Xiang T, Zhang W. Correlation Between Relative  
451 Nasopharyngeal Virus RNA Load and Lymphocyte Count Disease Severity in Patients with  
452 COVID-19. *Viral immunology*. 2020;10.
- 453 38. Luo M, Liu J, Jiang W, Yue S, Liu H, Wei S. IL-6 and CD8+ T cell counts combined  
454 are an early predictor of in-hospital mortality of patients with COVID-19. *Jci Insight*.  
455 2020;5(13):09.
- 456 39. McElvaney OJ, McEvoy N, McElvaney OF, Carroll TP, Murphy MP, Dunlea DM, et  
457 al. Characterization of the Inflammatory Response to Severe COVID-19 Illness. *American*  
458 *journal of respiratory and critical care medicine*. 2020;25.
- 459 40. Chen R, Sang L, Jiang M, Yang Z, Jia N, Fu W, et al. Longitudinal hematologic and  
460 immunologic variations associated with the progression of COVID-19 patients in China.  
461 *Journal of Allergy and Clinical Immunology*. 2020.
- 462 41. Wan S, Yi Q, Fan S, Lv J, Zhang X, Guo L, et al. Relationships among lymphocyte  
463 subsets, cytokines, and the pulmonary inflammation index in coronavirus (COVID-19)  
464 infected patients. *British Journal of Haematology*. 2020;189(3):428-37.
- 465 42. Chen X, Zhao B, Qu Y, Chen Y, Xiong J, Feng Y, et al. Detectable serum SARS-  
466 CoV-2 viral load (RNAemia) is closely correlated with drastically elevated interleukin 6  
467 (IL-6) level in critically ill COVID-19 patients. *Clinical infectious diseases : an official*  
468 *publication of the Infectious Diseases Society of America*. 2020;17.
- 469 43. Yang AP, Li HM, Tao WQ, Yang XJ, Wang M, Yang WJ, et al. Infection with  
470 SARS-CoV-2 causes abnormal laboratory results of multiple organs in patients. *Aging*.  
471 2020;12(11):10059-69.
- 472 44. Yuan X, Huang W, Ye B, Chen C, Huang R, Wu F, et al. Changes of hematological  
473 and immunological parameters in COVID-19 patients. *International Journal of Hematology*.  
474 2020.
- 475 45. Zhou Y, Han T, Chen J, Hou C, Hua L, He S, et al. Clinical and Autoimmune  
476 Characteristics of Severe and Critical Cases with COVID-19. *Clinical and Translational*  
477 *Science*. 2020.
- 478 46. Zhu Z, Cai T, Fan L, Lou K, Hua X, Huang Z, et al. Clinical value of immune-  
479 inflammatory parameters to assess the severity of coronavirus disease 2019. *International*  
480 *Journal of Infectious Diseases*. 2020.
- 481 47. Zhang Y, Li J, Zhan Y, Wu L, Yu X, Zhang W, et al. Analysis of serum cytokines in  
482 patients with severe acute respiratory syndrome. *Infection and immunity*. 2004;72(8):4410-5.
- 483 48. Hong KH, Choi JP, Hong SH, Lee J, Kwon JS, Kim SM, et al. Predictors of mortality  
484 in Middle East respiratory syndrome (MERS). *Thorax*. 2018;73(3):286-9.
- 485 49. Kim ES, Choe PG, Park WB, Oh HS, Kim EJ, Nam EY, et al. Clinical Progression  
486 and Cytokine Profiles of Middle East Respiratory Syndrome Coronavirus Infection. *Journal*  
487 *of Korean Medical Science*. 2016;31(11):1717-25.

- 488 50. Liu B, Li M, Zhou Z, Guan X, Xiang Y. Can we use interleukin-6 (IL-6) blockade for  
489 coronavirus disease 2019 (COVID-19)-induced cytokine release syndrome (CRS)? *Journal of*  
490 *Autoimmunity*. 2020;111:102452.
- 491 51. Wang W, Ye L, Ye L, Li B, Gao B, Zeng Y, et al. Up-regulation of IL-6 and TNF-  
492 alpha induced by SARS-coronavirus spike protein in murine macrophages via NF-kappaB  
493 pathway. *Virus Res*. 2007;128(1-2):1-8.
- 494 52. Zhou J, Chu H, Li C, Wong BH-Y, Cheng Z-S, Poon VK-M, et al. Active replication  
495 of Middle East respiratory syndrome coronavirus and aberrant induction of inflammatory  
496 cytokines and chemokines in human macrophages: implications for pathogenesis. *The*  
497 *Journal of infectious diseases*. 2014;209(9):1331-42.
- 498 53. Gadiant RA, Patterson PH. Leukemia inhibitory factor, Interleukin 6, and other  
499 cytokines using the GP130 transducing receptor: roles in inflammation and injury. *Stem cells*.  
500 1999;17(3):127-37.
- 501 54. Kalliolias GD, Ivashkiv LB. TNF biology, pathogenic mechanisms and emerging  
502 therapeutic strategies. *Nat Rev Rheumatol*. 2016;12(1):49-62.
- 503 55. Tanaka T, Narazaki M, Kishimoto T. Immunotherapeutic implications of IL-6  
504 blockade for cytokine storm. *Immunotherapy*. 2016;8(8):959-70.
- 505 56. Parsons PE, Eisner MD, Thompson BT, Matthay MA, Ancukiewicz M, Bernard GR,  
506 et al. Lower tidal volume ventilation and plasma cytokine markers of inflammation in  
507 patients with acute lung injury. *Critical care medicine*. 2005;33(1):1-6.
- 508 57. Wang C, Xie J, Zhao L, Fei X, Zhang H, Tan Y, et al. Alveolar macrophage activation  
509 and cytokine storm in the pathogenesis of severe COVID-19. 2020.
- 510 58. Chen Y, Thai P, Zhao Y-H, Ho Y-S, DeSouza MM, Wu R. Stimulation of airway  
511 mucin gene expression by interleukin (IL)-17 through IL-6 paracrine/autocrine loop. *Journal*  
512 *of Biological Chemistry*. 2003;278(19):17036-43.
- 513 59. McGonagle D, O'Donnell JS, Sharif K, Emery P, Bridgewood C. Immune  
514 mechanisms of pulmonary intravascular coagulopathy in COVID-19 pneumonia. *The Lancet*  
515 *Rheumatology*. 2020.
- 516 60. Hotchkiss RS, Monneret G, Payen D. Sepsis-induced immunosuppression: from  
517 cellular dysfunctions to immunotherapy. *Nature Reviews Immunology*. 2013;13(12):862-74.
- 518 61. Corazza F. Evaluation of Interleukine 6 (and Other Cytokines and Inflammatory  
519 Markers) in COVID-19 Patients With a Systemic Inflammatory Response Syndrome. In:  
520 Hospital BU, editor. April: ClinicalTrials.gov 2020.
- 521 62. Alosaimi B, Hamed ME, Naeem A, Alsharef AA, AlQahtani SY, AlDosari KM, et al.  
522 MERS-CoV infection is associated with downregulation of genes encoding Th1 and Th2  
523 cytokines/chemokines and elevated inflammatory innate immune response in the lower  
524 respiratory tract. *Cytokine*. 2020;126:154895.
- 525 63. Yoshikawa T, Hill T, Li K, Peters CJ, Tseng CT. Severe acute respiratory syndrome  
526 (SARS) coronavirus-induced lung epithelial cytokines exacerbate SARS pathogenesis by  
527 modulating intrinsic functions of monocyte-derived macrophages and dendritic cells. *J Virol*.  
528 2009;83(7):3039-48.
- 529 64. Cheung CY, Poon LL, Ng IH, Luk W, Sia S-F, Wu MH, et al. Cytokine responses in  
530 severe acute respiratory syndrome coronavirus-infected macrophages in vitro: possible  
531 relevance to pathogenesis. *Journal of virology*. 2005;79(12):7819-26.
- 532 65. Zhang F, Mears JR, Shakib L, Beynor JI, Shanaj S, Korsunsky I, et al. IFN- $\gamma$  and  
533 TNF- $\alpha$  drive a CXCL10+ CCL2+ macrophage phenotype expanded in severe COVID-19 and  
534 other diseases with tissue inflammation. *bioRxiv*. 2020.
- 535 66. Tincati C, Cannizzo ES, Giacomelli M, Badolato R, Monforte AdA, Marchetti G.  
536 Heightened Circulating Interferon-Inducible Chemokines, and Activated Pro-Cytolytic Th1-

- 537 Cell Phenotype Features Covid-19 Aggravation in the Second Week of Illness. *Frontiers in*  
538 *immunology*. 2020;11.
- 539 67. Rollins BJ, Yoshimura T, Leonard EJ, Pober JS. Cytokine-activated human  
540 endothelial cells synthesize and secrete a monocyte chemoattractant, MCP-1/JE. *Am J*  
541 *Pathol*. 1990;136(6):1229-33.
- 542 68. Romano M, Sironi M, Toniatti C, Polentarutti N, Fruscella P, Ghezzi P, et al. Role of  
543 IL-6 and its soluble receptor in induction of chemokines and leukocyte recruitment.  
544 *Immunity*. 1997;6(3):315-25.
- 545 69. van den Borne P, Quax PH, Hoefer IE, Pasterkamp G. The multifaceted functions of  
546 CXCL10 in cardiovascular disease. *BioMed research international*. 2014;2014.
- 547 70. Xu Z-S, Shu T, Kang L, Wu D, Zhou X, Liao B-W, et al. Temporal profiling of  
548 plasma cytokines, chemokines and growth factors from mild, severe and fatal COVID-19  
549 patients. *Signal transduction and targeted therapy*. 2020;5(1):1-3.
- 550 71. Lupieri A, Smirnova NF, Solinhac R, Malet N, Benamar M, Saoudi A, et al. Smooth  
551 muscle cells-derived CXCL10 prevents endothelial healing through PI3K $\gamma$ -dependent T cells  
552 response. *Cardiovascular Research*. 2020;116(2):438-49.
- 553 72. Qin L, Li X, Shi J, Yu M, Wang K, Tao Y, et al. Gendered effects on inflammation  
554 reaction and outcome of COVID-19 patients in Wuhan. *Journal of Medical Virology*. 2020.
- 555 73. Torcia MG, Nencioni L, Clemente AM, Civitelli L, Celestino I, Limongi D, et al. Sex  
556 differences in the response to viral infections: TLR8 and TLR9 ligand stimulation induce  
557 higher IL10 production in males. *PloS one*. 2012;7(6):e39853.
- 558 74. Sankaran-Walters S, Macal M, Grishina I, Nagy L, Goulart L, Coolidge K, et al. Sex  
559 differences matter in the gut: effect on mucosal immune activation and inflammation.  
560 *Biology of sex differences*. 2013;4(1):1-12.
- 561 75. Abdullah M, Chai P-S, Chong M-Y, Tohit ERM, Ramasamy R, Pei CP, et al. Gender  
562 effect on in vitro lymphocyte subset levels of healthy individuals. *Cellular immunology*.  
563 2012;272(2):214-9.
- 564 76. Huang H, Luo Y, Liang Y, Long X, Peng Y, Liu Z, et al. CD4<sup>+</sup> CD25<sup>+</sup> T cells in  
565 primary malignant hypertension related kidney injury. *Scientific Reports*. 2016;6(1):1-9.
- 566 77. Rucker AJ, Crowley SD. The role of macrophages in hypertension and its  
567 complications. *Pflügers Archiv-European Journal of Physiology*. 2017;469(3-4):419-30.
- 568 78. Silawal S, Willauschus M, Schulze-Tanzil G, Gögele C, Geßlein M, Schwarz S. Il-10  
569 could play a role in the interrelation between diabetes mellitus and osteoarthritis.  
570 *International journal of molecular sciences*. 2019;20(3):768.
- 571 79. Alba AC, Alexander PE, Chang J, MacIsaac J, DeFry S, Guyatt GH. High statistical  
572 heterogeneity is more frequent in meta-analysis of continuous than binary outcomes. *Journal*  
573 *of clinical epidemiology*. 2016;70:129-35.

574

575

576

577

578

579

580

581  
582  
583  
584  
585  
586  
587  
588  
589  
590  
591  
592  
593  
594  
595  
596  
597  
598  
599  
600  
601  
602  
603




Figure 1. The PRISMA flow diagram of study inclusion/exclusion process

605 **Table 1. Characteristics of included studies**

Author, year of study (ref)	Diseases	Country	Study type	Severe cases			Non-severe cases			Quality
				Sample size	Age	Study type	Sample size	Age	Male %	
<b>Chen Guang, 2020 (32)</b>	COVID-19	China	Retrospective study, single centre	11	61[IQR 56.5-66]	91 % male	10	52.0 [IQR42.8–56.0]	70% male	Good
<b>Gao Yong, 2020 (33)</b>	COVID-19	China	Retrospective study, single centre	15	45.20±7.68	60 % males	28	42.96 ±14.00	60% males	Good
<b>Han Huan, 2020 (34)</b>	COVID-19	China	Retrospective study, single centre	17	65.1±14.4	52 % males	42	58.3±12.6	48% males	Moderate
<b>He Susu, 2020 (35)</b>	COVID-19	China	Retrospective study, single centre	33	54±12.5	55 % males	60	44±12.5	52% males	Good
<b>Herold Tobias, 2020 (36)</b>	COVID-19	Germany	Prospective study, single centre	13	64 [IQR 45-81]	91% males	27	58 [IQR18-84]	58% males	Good
<b>Liu Yang, 2020 (37)</b>	COVID-19	China	Retrospective study, single centre	30	NA	NA	46	N.A.	NA	Good
<b>Luo Miao, 2020 (38)</b>	COVID-19	China	Retrospective study, two centres	201	69.00[IQR 62.00–78.00]	66.2 % males	817	57.00 [IQR46.0–66.0]	47.5% males	Good
<b>McElvaney Oliver J, 2020 (39)</b>	COVID-19	Ireland	Retrospective study, single centre	20	54.3±18.2	65 % males	20	56.6±17.3	60% males	Good
<b>Chen Ruchong, 2020 (40)</b>	COVID-19	China	Retrospective cohort study, multiple centres	48	61.4±13.6	79 % males	354	67.3±12.1	52.8% males	Good
<b>Wan Suxin, 2020 (41)</b>	COVID-19	China	Cross-sectional, single centre	21	61.29±15.55	52 % males	102	43.05± 13.12	53% males	Good
<b>Xiaohua Chen, 2020 (42)</b>	COVID-19	China	Retrospective study, single centre	17	79.6±12.6	88.2 % males	21	52.8±14.2	61.9% males	Good
<b>Yang A. P, 2020 (43)</b>	COVID-19	China	Retrospective study, single centre	24	57.9±11.8	55 % males	69	42.1±18.6	75% males	Good
<b>Yuan X, 2020 (44)</b>	COVID-19	China	Cross-sectional, two centres	46	68 [IQR 61-76]	45.7 % males	60	66 [IQR52-69]	49.2% males	Good
<b>Zhou Yaqing, 2020 (45)</b>	COVID-19	China	Retrospective study, single centre	13	67.38 ± 13.36	77 % males	8	64.00± 15.51	37.5% males	Good
<b>Zhu Zhe, 2020 (46)</b>	COVID-19	China	Retrospective study, single centre	16	57.50±11.70	56.25 % males	111	49.95± 15.52	65.77% males	Good
<b>Zhang Yuanchun, 2004 (47)</b>	SARS	China	Retrospective study, single centre	30	45.4 [IQR19–86]	70 % males	30	44.1 [IQR17–80]	56.6% males	Good

<b>Hong Ki-Ho, 2018 (48)</b>	MERS	South Korea	Retrospective study, multiple centres	6	59±8	83 % males	24	46±13	58% males	Good
<b>Kim Eu Suk, 2016 (49)</b>	MERS	South Korea	Retrospective study, multiple centres	9	62±13.5	77 % males	8	54.25±10.9	75% males	Good

606 1 The age is expressed as mean ± S.D. or median [IQR].

607

608

609 **Table 2.** Details on the pro-inflammatory and anti-inflammatory cytokines profile among all study  
 610 participants.

IL-1		Severe	Non-severe	Significant
Authors (Ref)	Diseases	ng/ml mean $\pm$ SD		
Chen Guang (32)	COVID-19	5 $\pm$ 0.1	5 $\pm$ 0.1	No
McElvaney Oliver J (39)	COVID-19	40.8 $\pm$ 10.4	13.7 $\pm$ 5.8	Yes
Liu Yang (37)	COVID-19	6.7 $\pm$ 2	6.3 $\pm$ 1.3	No
Yang A. P (43)	COVID-19	38.1 $\pm$ 37.4	19.5 $\pm$ 12.4	No
IL-2		Severe	Non-severe	Significant
Authors (Ref)	Diseases	ng/ml mean $\pm$ SD		
Yuan X (44)	COVID-19	3.4 $\pm$ 0.41	3.5 $\pm$ 0.5	No
Han Huan (34)	COVID-19	3.4 $\pm$ 0.17	3.4 $\pm$ 0.23	No
He Susu (35)	COVID-19	1.1 $\pm$ 0.55	1.4 $\pm$ 1.16	No
Zhu Zhe (46)	COVID-19	1 $\pm$ 0.22	1.04 $\pm$ 0.2	No
Yang A. P (43)	COVID-19	8.1 $\pm$ 6.03	2.25 $\pm$ 1.01	Yes
IL-6		Severe	Non-severe	Significant
Authors (Ref)	Diseases	ng/ml mean $\pm$ SD		
Yuan X. (44)	COVID-19	17.3 $\pm$ 5.6	9.5 $\pm$ 3.1	Yes
Liu Yang (37)	COVID-19	37.4 $\pm$ 21.8	10.7 $\pm$ 5.7	Yes
Luo Miao (38)	COVID-19	68.7 $\pm$ 18.5	7.2 $\pm$ 2.3	Yes
Chen Guang (32)	COVID-19	55.5 $\pm$ 27	16.6 $\pm$ 6.8	Yes
Xiaohua Chen (42)	COVID-19	66.4 $\pm$ 21.6	13.9 $\pm$ 6.8	Yes
Gao Yong (33)	COVID-19	38.6 $\pm$ 10.5	12.6 $\pm$ 4.8	Yes

Herold Tobias (36)	COVID-19	158.7±125.5	63.9±52.3	Yes
Chen Ruchong (40)	COVID-19	8.7±1.8	7.6±0.7	Yes
Han Huan (34)	COVID-19	32.3±16.7	6.7±0.9	Yes
He Susu (35)	COVID-19	12.7±8.2	4.6±4.3	Yes
Zhu Zhe (46)	COVID-19	26±13.4	4.9±1.3	Yes
Wan Suxin (41)	COVID-19	37.8±3.9	13.4±0.6	Yes
McElvaney Oliver J (39)	COVID-19	169.4±35.4	45.9±12.4	Yes
Zhou Yaqing (45)	COVID-19	17.2±5.6	35.3±1.9	No
Yang A. P (43)	COVID-19	326.5±299.4	30.8±27.4	Yes
Hong Ki-Ho (48)	MERS	85.3±66.9	12.5±13.8	Yes
Kim Eu Suk (49)	MERS	157±38.3	29.5±18.5	Yes
Zhang Yuanchun (47)	SARS	517±769	163±796	Yes
IL-17		Severe	Non-severe	Significant
Authors (Ref)	Diseases	ng/ml mean ± SD		
Wan Suxin (41)	COVID-19	1.16±0.03	1.1±0.01	No
Yang A. P (43)	COVID-19	3.4±2.5	3.8±2.5	No
TNF		Severe	Non-severe	Significant
Authors (Ref)	Diseases	ng/ml mean ± SD		
Chen Guang (32)	COVID-19	10.55±0.4	7.4±0.8	Yes
Han Huan (34)	COVID-19	8.7±2.6	5.2±0.4	Yes
He Susu (35)	COVID-19	1.13±0.3	1.4±0.5	No
Luo Miao (38)	COVID-19	11.3±1.7	6.9±0.5	Yes
Wan Suxin (41)	COVID-19	2.9±0.2	4.1±0.5	No

Yuan X. (44)	COVID-19	5.1±1.6	4.4±0.8	No
Zhu Zhe (46)	COVID-19	1.5±0.1	1.4±0.1	No
Yang A. P (43)	COVID-19	284.2±266.3	17.7±13.6	No
Zhang Yuanchun (47)	SARS	57.8±5.7	60.1±4.4	No
INF- $\gamma$		Severe	Non-severe	Significant
Authors (Ref)	Diseases	ng/ml mean $\pm$ SD		
Han Huan (34)	COVID-19	3.4±0.3	3.3±0.4	No
He Susu (35)	COVID-19	2.1±0.6	1.9±0.6	No
Wan Suxin (41)	COVID-19	6.9±0.6	5.1±0.3	No
Yuan X. (44)	COVID-19	2.9±0.4	2.9±0.4	No
Zhu Zhe (46)	COVID-19	1.9±0.3	1.2±0.1	Yes
Yang A. P (43)	COVID-19	42.2±37.7	19±16.8	No
Zhang Yuanchun (47)	SARS	86.5±20.4	63±20.4	No
IL-4		Severe	Non-severe	Significant
Authors (Ref)	Diseases	ng/ml mean $\pm$ SD		
Yuan X. (44)	COVID-19	2.9±0.5	2.9±0.44	No
Han Huan (34)	COVID-19	3.3±0.2	3.4±0.2	Yes
He Susu (35)	COVID-19	1.5±0.3	1.7±0.4	No
Zhu Zhe (46)	COVID-19	1.2±0.4	1.9±0.19	No
Wan Suxin (41)	COVID-19	1.8±0.1	1.7±0.02	No
Yang A. P (43)	COVID-19	1.8±0.7	2.7±1.7	No
Zhang Yuanchun (47)	SARS	110±12	109±13	No
IL-10		Severe	Non-severe	Significant

Authors (Ref)	Diseases	ng/ml mean $\pm$ SD		
Chen Guang (32)	COVID-19	10.8 $\pm$ 0.61	5.8 $\pm$ 1.03	Yes
Han Huan (34)	COVID-19	8.7 $\pm$ 2.6	5.2 $\pm$ 0.39	Yes
He Susu (35)	COVID-19	4.9 $\pm$ 2.6	3.5 $\pm$ 0.9	Yes
Luo Miao (38)	COVID-19	10 $\pm$ 1.7	5.6 $\pm$ 0.3	Yes
McElvaney Oliver J (39)	COVID-19	47.3 $\pm$ 8.7	54.7 $\pm$ 7.9	No
Wan Suxin (41)	COVID-19	4.6 $\pm$ 0.2	2.5 $\pm$ 0.03	Yes
Liu Yang (37)	COVID-19	7.7 $\pm$ 1.6	5.22 $\pm$ 0.22	No
Yuan X. (44)	COVID-19	4.8 $\pm$ 0.6	4.3 $\pm$ 0.5	No
Zhu Zhe (46)	COVID-19	6.8 $\pm$ 1.9	3.3 $\pm$ 0.4	Yes
Yang A. P (43)	COVID-19	12.6 $\pm$ 9.6	3.9 $\pm$ 2.5	Yes
Zhang Yuanchun (47)	SARS	49.7 $\pm$ 12.3	47 $\pm$ 5.3	No

611  
612

613

614 **Table 3.** Details on the chemokines profile among all study participants.

IL-8		Severe	Non-severe	Significant
Authors (Ref)	Diseases	ng/ml mean $\pm$ SD		
Chen Guang (32)	COVID-19	34.1 $\pm$ 9.02	15.8 $\pm$ 8.6	no
Luo Miao (38)	COVID-19	33.8 $\pm$ 6.6	12.9 $\pm$ 1.8	Yes
McElvaney Oliver J (39)	COVID-19	115.5 $\pm$ 23.2	45.2 $\pm$ 12	Yes
Liu Yang (37)	COVID-19	43.4 $\pm$ 30.2	10.2 $\pm$ 3.02	Yes
Yang A. P (43)	COVID-19	1100.1 $\pm$ 994.7	131.63 $\pm$ 113.6	Yes
Zhang Yuanchun (47)	SARS	143 $\pm$ 41	165 $\pm$ 51	Yes
CXCL10/IP10		Severe	Non-severe	Significant
Authors (Ref)	Diseases	ng/ml mean $\pm$ SD		
Kim Eu Suk (49)	MERS	2506.8 $\pm$ 876.7	327.3 $\pm$ 160.4	Yes
Hong Ki-Ho (48)	MERS	815.5 $\pm$ 230.8	247.8 $\pm$ 35.8	Yes
CCL2/MCP-1		Severe	Non-severe	sig
Authors (Ref)	Diseases	ng/ml mean $\pm$ SD		
Hong Ki-Ho (48)	MERS	888.8 $\pm$ 146.8	127.5 $\pm$ 26.5	Yes

615

616

617